ESR1 and breast cancer: Specifically for rat HR+ mammary tumors, Dischinger et al. [270] have demonstrated that the CRISPR-mediated germline knockout of Nf1, a regulatory gene in the RAS pathway linked to increased luminal BC risk, leads to estrogen-dependent ER+ mammary tumors in SD rats [270, 271].